Lyell Immunopharma (LYEL) Capital Expenditures (2020 - 2026)
Lyell Immunopharma (LYEL) posted Capital Expenditures of $89000.0 for Q1 2026, down 88.59% sequentially from $780000.0 in Q4 2025, and down 42.58% YoY from $155000.0 in Q1 2025.
Lyell Immunopharma (LYEL) Capital Expenditures (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Capital Expenditures for 7 years, with the latest figure at $89000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 42.58% year-over-year to $89000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $714000.0 (up 165.43% YoY) and the FY2025 annual result came in at $780000.0, up 441.67% from the prior year.
- Capital Expenditures fell to $89000.0 in Q1 2026 per LYEL's latest filing, from $780000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $16.1 million in Q3 2022 and troughed at -$18.4 million in Q4 2022.
- A 5-year average of $295529.4 and a median of $155000.0 in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures jumped 1507.24% in 2022, then plunged 211.89% in 2025.
- Over 5 years, Capital Expenditures stood at -$18.4 million in 2022, then surged by 114.61% to $2.7 million in 2023, then tumbled by 110.28% to -$276000.0 in 2024, then soared by 382.61% to $780000.0 in 2025, then tumbled by 88.59% to $89000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $89000.0, $780000.0, and -$414000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 153,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 153,000.00 |
| Jun 30, 2026 | 153,000.00 |
| Mar 31, 2026 | 89,000.00 |
| Mar 31, 2026 | 89,000.00 |
| Dec 31, 2025 | 780,000.00 |
| Dec 31, 2025 | 780,000.00 |
| Sep 30, 2025 | -414,000.00 |
| Sep 30, 2025 | -414,000.00 |
| Jun 30, 2025 | 259,000.00 |
| Jun 30, 2025 | 259,000.00 |
| Mar 31, 2025 | 155,000.00 |
| Mar 31, 2025 | 155,000.00 |
| Dec 31, 2024 | -276,000.00 |
| Dec 31, 2024 | -276,000.00 |
| Sep 30, 2024 | 370,000.00 |
| Sep 30, 2024 | 370,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |